N-3 fatty acids

Role in treating dyslipidemias and preventing cardiovascular disease

Thomas A. Barringer, William Harris, Jennifer A. Fleming, Penny M. Kris-Etherton

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Long-chain n-3 fatty acids have an important role in treating dyslipidemia characterized by elevated triglycerides. Because the degree of triglyceride lowering is dependent upon dose of the n-3 fatty acids as well as the baseline triglyceride level, high doses (3–4 g) are especially effective in treating very high triglycerides (> 500 mg/dL), a condition associated with an increased risk of pancreatitis. Various formulations are available, with differences in bioavailability and effects on specific lipid/lipoprotein parameters. The clinical significance of these differences is unclear, but warrants further study. All of the therapeutic formulations are well tolerated and have an excellent safety record in clinical trials. The role of long-chain n-3 fatty acids as a therapy to reduce the incidence of cardiovascular events is still being defined.

Original languageEnglish (US)
Title of host publicationDyslipidemias: Pathophysiology, Evaluation and Management
PublisherHumana Press Inc.
Pages355-370
Number of pages16
ISBN (Print)9781607614241, 9781607614234
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Omega-3 Fatty Acids
Dyslipidemias
Triglycerides
Cardiovascular Diseases
Pancreatitis
Biological Availability
Lipoproteins
Clinical Trials
Lipids
Safety
Incidence
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Barringer, T. A., Harris, W., Fleming, J. A., & Kris-Etherton, P. M. (2015). N-3 fatty acids: Role in treating dyslipidemias and preventing cardiovascular disease. In Dyslipidemias: Pathophysiology, Evaluation and Management (pp. 355-370). Humana Press Inc.. https://doi.org/10.1007/978-1-60761-424-1_21

N-3 fatty acids : Role in treating dyslipidemias and preventing cardiovascular disease. / Barringer, Thomas A.; Harris, William; Fleming, Jennifer A.; Kris-Etherton, Penny M.

Dyslipidemias: Pathophysiology, Evaluation and Management. Humana Press Inc., 2015. p. 355-370.

Research output: Chapter in Book/Report/Conference proceedingChapter

Barringer, TA, Harris, W, Fleming, JA & Kris-Etherton, PM 2015, N-3 fatty acids: Role in treating dyslipidemias and preventing cardiovascular disease. in Dyslipidemias: Pathophysiology, Evaluation and Management. Humana Press Inc., pp. 355-370. https://doi.org/10.1007/978-1-60761-424-1_21
Barringer TA, Harris W, Fleming JA, Kris-Etherton PM. N-3 fatty acids: Role in treating dyslipidemias and preventing cardiovascular disease. In Dyslipidemias: Pathophysiology, Evaluation and Management. Humana Press Inc. 2015. p. 355-370 https://doi.org/10.1007/978-1-60761-424-1_21
Barringer, Thomas A. ; Harris, William ; Fleming, Jennifer A. ; Kris-Etherton, Penny M. / N-3 fatty acids : Role in treating dyslipidemias and preventing cardiovascular disease. Dyslipidemias: Pathophysiology, Evaluation and Management. Humana Press Inc., 2015. pp. 355-370
@inbook{bcddca18c7874e72b2ffc2f9fea3d245,
title = "N-3 fatty acids: Role in treating dyslipidemias and preventing cardiovascular disease",
abstract = "Long-chain n-3 fatty acids have an important role in treating dyslipidemia characterized by elevated triglycerides. Because the degree of triglyceride lowering is dependent upon dose of the n-3 fatty acids as well as the baseline triglyceride level, high doses (3–4 g) are especially effective in treating very high triglycerides (> 500 mg/dL), a condition associated with an increased risk of pancreatitis. Various formulations are available, with differences in bioavailability and effects on specific lipid/lipoprotein parameters. The clinical significance of these differences is unclear, but warrants further study. All of the therapeutic formulations are well tolerated and have an excellent safety record in clinical trials. The role of long-chain n-3 fatty acids as a therapy to reduce the incidence of cardiovascular events is still being defined.",
author = "Barringer, {Thomas A.} and William Harris and Fleming, {Jennifer A.} and Kris-Etherton, {Penny M.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-1-60761-424-1_21",
language = "English (US)",
isbn = "9781607614241",
pages = "355--370",
booktitle = "Dyslipidemias: Pathophysiology, Evaluation and Management",
publisher = "Humana Press Inc.",

}

TY - CHAP

T1 - N-3 fatty acids

T2 - Role in treating dyslipidemias and preventing cardiovascular disease

AU - Barringer, Thomas A.

AU - Harris, William

AU - Fleming, Jennifer A.

AU - Kris-Etherton, Penny M.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Long-chain n-3 fatty acids have an important role in treating dyslipidemia characterized by elevated triglycerides. Because the degree of triglyceride lowering is dependent upon dose of the n-3 fatty acids as well as the baseline triglyceride level, high doses (3–4 g) are especially effective in treating very high triglycerides (> 500 mg/dL), a condition associated with an increased risk of pancreatitis. Various formulations are available, with differences in bioavailability and effects on specific lipid/lipoprotein parameters. The clinical significance of these differences is unclear, but warrants further study. All of the therapeutic formulations are well tolerated and have an excellent safety record in clinical trials. The role of long-chain n-3 fatty acids as a therapy to reduce the incidence of cardiovascular events is still being defined.

AB - Long-chain n-3 fatty acids have an important role in treating dyslipidemia characterized by elevated triglycerides. Because the degree of triglyceride lowering is dependent upon dose of the n-3 fatty acids as well as the baseline triglyceride level, high doses (3–4 g) are especially effective in treating very high triglycerides (> 500 mg/dL), a condition associated with an increased risk of pancreatitis. Various formulations are available, with differences in bioavailability and effects on specific lipid/lipoprotein parameters. The clinical significance of these differences is unclear, but warrants further study. All of the therapeutic formulations are well tolerated and have an excellent safety record in clinical trials. The role of long-chain n-3 fatty acids as a therapy to reduce the incidence of cardiovascular events is still being defined.

UR - http://www.scopus.com/inward/record.url?scp=84956730937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956730937&partnerID=8YFLogxK

U2 - 10.1007/978-1-60761-424-1_21

DO - 10.1007/978-1-60761-424-1_21

M3 - Chapter

SN - 9781607614241

SN - 9781607614234

SP - 355

EP - 370

BT - Dyslipidemias: Pathophysiology, Evaluation and Management

PB - Humana Press Inc.

ER -